VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
Here's Why Agios Stock Plummeted More Than 20% on Monday
Improved Revenues Required Before CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock's 28% Jump Looks Justified
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
CytomX Therapeutics Analyst Ratings
H.C. Wainwright Maintains CytomX(CTMX.US) With Hold Rating
Piper Sandler Maintains CytomX(CTMX.US) With Buy Rating, Cuts Target Price to $3.25
CytomX Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results.
CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript Summary
12 Health Care Stocks Moving In Friday's Pre-Market Session
Barclays Maintains CytomX(CTMX.US) With Buy Rating, Maintains Target Price $3.5
CytomX Therapeutics (CTMX) Receives a Buy From Barclays
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Posts Q3 Revenue $33.4M
CytomX GAAP EPS of $0.07 Beats by $0.23, Revenue of $33.4M Beats by $16.3M
CytomX | 8-K: CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Express News | CytomX Therapeutics Q3 Net Income USD 5.736 Million
Express News | CytomX Therapeutics Q3 Operating Income USD 4.111 Million